skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The bevacizumab experience in advanced renal cell carcinoma

Review

(1693) Views  (707) Full article downloads

Authors: Lauren C Harshman, Sandy Srinivas

Published Date September 2010 Volume 2010:3 Pages 179 - 189
DOI: http://dx.doi.org/10.2147/OTT.S8157

Lauren C Harshman, Sandy Srinivas
Division of Oncology, Stanford University School of Medicine, Stanford, California, USA

Abstract: Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9–10 months are ­comparable to the other approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages include a different toxicity profile and assurance of ­administration compliance given its intravenous formulation. Enthusiasm for its use is blunted by the increased costs, the potential infusion-related reactions, the associated interferon-related toxicities, and the inconvenience of its nonoral formulation. Further study is warranted to assess its efficacy both as a single agent and in combination with the targeted agents and other immunotherapies. With multiple agents now available for the treatment of advanced RCC, identification of patient and tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence of subsequent therapies is imperative.

Keywords: bevacizumab, renal cell carcinoma, interferon alfa







Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
L-CBM signaling in lymphocyte development and function
Dynamic changes to survivin subcellular localization are initiated by DNA damage
Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial